



## Vote-by-mail form for the GENERAL MEETING OF SHAREHOLDERS held on 16/17.04.2024

The undersigned, number, number, domiciled in	_ [ <i>individual shareholder's</i> full name], identified , issued by, , National
Identification Number, or	
The undersigned	, registered at the Trade Register Office under n Code, legally represented
shareholder on the reference Date, i.e. 04.04 registered at the Trade Register Office under number ofshares, representingthe Company, which grant mevotrepresenting% of the total voting right	per J22/285/1991, fiscal code 1973096, holding a% of the total <b>671,338,040</b> shares issued by ing rights in the General Meetings of Shareholders
being aware of the Agendas for the General Meetin on 16.04.2024, at 10:00 am and 12:00 am, and respons the event that the conditions for organizing the	Dectively <b>17.04.2024</b> , at 10:00 am and 12:00 am,

and in accordance with Article 208 of the ASF Regulation no. 5/2018, I hereby exercise my right to vote by mail, as follows:

on the first above-mentioned date) and being aware of the documentation provided by Antibiotice

No.	Agenda for		Option		
110.	Extraordinary General Meeting of Shareholders	for	against	abstention	
0	1	2	3	4	
1.	Approval for amending the Articles of Incorporation of Antibiotice S.A. Chapter V Management Board: amending Art. 29, Art. 30, Art. 39, Art. 41, Art. 42 and insertion of new article Art. 40 <sup>1</sup> (according to Annex 1 attached).				
2.	Approval for relocating the Antibiotice S.A. Representative office in Vietnam from the address: Vietnam, Hanoi, Duy Tan St, Cau Giay District, Dich Vong Hau Ward, alley 82, tower 3A, room 807, the 8 <sup>th</sup> floor to the address: Vietnam, Hanoi, 78 Duy Tan St., Cau Giay District, Dich Vong Hau Ward, Sannam building, the 8 <sup>th</sup> floor.				

in connection with these agendas,

No.	Agenda for		Optio	n
	Ordinary General Meeting of Shareholders	for	against	abstention
1.	Approval of the Management Report at 31.12.2023.	2	3	4
2.	Submission of the Statutory Auditor's Report;			
3.	Approval of the financial statements for the financial year 2023 based on the Management Report and the Financial Auditor's Report.			
4.	Approval of the distribution of net profit for 2023, fixing of the gross dividend per share and setting of the date of 11.10.2024 as the payment date.			
5.	Approval for registering the unsolicited and unclaimed dividends for the financial year 2019 as revenues.			
6.	Approval of the degree in which the non-executive administrators achieved the performance indicators for 2023.			
7.	Approval of the degree in which the executive administrator/general director achieved the performance indicators for 2023.			
8.	Approval of the discharge from administration of the administrators for the activity carried out in the financial year 2023, based on the submitted reports.			
9.	Acknowledgement that the mandate contracts of the Management Board members ceased as a result of completing the term for which they were concluded;			
10.	Approval for renewing the mandate as an executive administrator of the General Director for a 4-year period, between 19.04.2024 - 19.04.2028, pursuant to art. 28 para. 8 of GEO no. 109/2011 on the corporate governance of public enterprises, as a result of carrying out the procedure established by art. 25 of the Annex to GD no. 639/2023 for the approval of the methodological rules for applying the Government Emergency Ordinance no. 109/2011 on the corporate governance of public enterprises.			
11.	Approval of the appointment of 6 (six) interim non-executive administrators for 5-month mandates which can be extended for good reasons up to 7 months. If the procedure for the selection and nomination of the permanent administrators initiated according to decision no. 4 of 14.09.2023 of the General Meeting of Shareholders will be completed before the expiration of the period for which the interim administrators are appointed, the permanent administrators will be appointed immediately by the General Meeting of Shareholders, and the mandate of the interim administrators will cease.  The list containing information on the name, place of residence and professional qualification of the persons proposed for the position of administrator is published on the company's website at the shareholders' disposal, and can be consulted and completed by them. The deadline for receiving proposals of candidates for the positions of administrators is 08.04.2024.			
12.	Setting of the 2024 performance indicators for the non-executive administrators.			
13.	Setting of the 2024 performance indicators for the executive administrator/general director.			

14.	Approval of the mandate contract of the executive administrator/general director for the period 19.04.2024 - 19.04.2028.		
15.	Approval of the mandate contracts of the interim non-executive administrators for the period 19.04.2024 - 19.09.2024.		
16.	Approval of the addenda to the mandate contracts of the non-executive administrators including the key performance indicators for 2024.		
17.	Approval of the addenda to the mandate contract of the executive administrator/general director including the key performance indicators for 2024.		
18.	Approval of the Management Plan, updated with the new performance indicators.		
19.	Approval of the remuneration report for 2023.		
20.	Approval of the remunerations for the Management Board members according to the mandate contract.		
21.	Approval of the date of 24.09.2024 as the registration date for identifying the shareholders on whom the effects of the adopted decisions are reflected, in accordance with the provisions of art. 86, para. 1 of Law 24/2017 on issuers of financial instruments and market operations, and setting the date of 23.09.2024 as the exdate.		

## I hereby attach:

- Certified copy of the shareholder's ID for individual shareholders (Identity card/passport/residence permit);
- Copy of the registration certificate for the legal persons/entities;
- Certified copy of the ID with respect to authorized agents/ attorneys-in-fact who are individuals (Identity card/passport/residence permit), if applicable;
- Special Power of Attorney for the agent/attorney-in-fact, in original (if applicable). Contact phone number

I/The undersigned, am fully and exclusively liable for the stipulations contained therein, in my capacity as shareholder of Antibiotice trading company.

Date \_\_\_\_\_\_

Individual shareholder

(Full name of the shareholder - in capitals)

(Shareholder's signature)

Corporate shareholder

(Name of the shareholder - in capitals)

Investors Relations	
Vote-by-mail form - GMS	16/17.04.2024

(Full name and position of the shareholder's legal representative - in capitals)
(Seal and signature of the shareholder's legal representative)
Contact phone no

(\*) to be completed for entities/corporate shareholders only.

The voting form by mail will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting.

In the event of updating the Vote-by-mail form, please check the requirements in the GM Convening Notice starting with the 16<sup>th</sup> day after the publication of the Convening Notice.

After filling in and signing the Vote by mail, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice Registrar's Office by 14.04.2024, 10:00 am at the latest.